How to Navigate China’s Patent Linkage System for Biologics: 2026 Guide

China’s Patent Linkage System (药品专利链接制度, Drug Patent Linkage System, yàopǐn zhuānlì liànjiē zhìdù) formally established in 2021 and fully operational by 2026, creates a 9-month stay period for biosimilar applications and a 12-month patent challenge window that foreign biologics companies must master to protect market exclusivity in the world’s second-largest pharmaceutical market, valued at over USD 140 billion.

The system, officially called the “Drug Patent Dispute Early Resolution Mechanism” (药品专利纠纷早期解决机制, yàopǐn zhuānlì jiūfēn zǎoqī jiějué jīzhì), was designed to balance innovation incentives with generic and biosimilar market access. For biologics — characterized by complex manufacturing processes and multiple patent layers — the stakes are particularly high. Unlike small-molecule drugs that typically rely on a single compound patent, a single biologic product may involve 10–25+ separate patents covering formulation, manufacturing methods, cell lines, purification processes, and indications. In 2025 alone, the China National Intellectual Property Administration (CNIPA) received 47 patent linkage cases involving biologics, a 34% increase from 2024, signaling rapidly escalating enforcement activity.

How the Patent Linkage System Works for Biologics in 2026

The linkage system applies to all chemical drugs and biologics approved by the National Medical Products Administration (国家药品监督管理局, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú). For biologics, the mechanism triggers when a biosimilar applicant files for marketing approval and simultaneously declares the patent status of the reference product. The system operates on a “list, challenge, stay, and resolve” framework.

First, the innovator company must register relevant patents on the China Patent Linkage Platform (中国上市药品专利信息登记平台, zhōngguó shàngshì yàopǐn zhuānlì xìnxī dēngjì píngtái) within 30 days of drug approval. In 2025, the NMPA introduced a mandatory validation step requiring patent registrants to submit a patent-claim-mapping table that links each patent to specific biologic product characteristics — a measure that reduced registration disputes by 22% but increased compliance costs for originators by an estimated RMB 350,000 per product per year.

When a biosimilar applicant files, it must provide one of four declarations: (1) no relevant patent registered, (2) the relevant patent has expired, (3) the patent will expire before the applicant obtains marketing approval, or (4) the relevant patent is invalid or the biosimilar does not fall within its scope. The last declaration triggers a 9-month stay of NMPA approval, during which the patent holder can sue at the Beijing Intellectual Property Court or petition for patent invalidation at CNIPA. As of early 2026, the average resolution time for biologic patent linkage disputes is 7.2 months, down from 11.4 months in 2023, thanks to specialized biologics patent panels.

Critical Challenges Specific to Biologics Patent Linkage

Biologics present three structural challenges that make the linkage system fundamentally different from its application to small-molecule drugs. First, the “patent cliff” for biologics is rarely sharp — a single product may have patents expiring at different times across 2026–2035, creating a staggered biosimilar entry window. Second, manufacturing process patents are notoriously difficult to “map” to a biosimilar’s abbreviated approval pathway, which relies on analytical similarity rather than full clinical trials. Third, China’s patent linkage system does not require biosimilar applicants to provide their full manufacturing process details until patent litigation is underway, creating an information asymmetry problem for innovators.

In response to these challenges, the NMPA and the China National Intellectual Property Administration jointly issued the “Implementation Measures for Patent Dispute Early Resolution for Biological Products” in November 2025 (试行, shìxíng, pilot implementation). The measures require biosimilar applicants to submit a manufacturing-process overview (生产工艺概述, shēngchǎn gōngyì gàishù) at the time of the patent declaration, giving innovators a baseline to assess infringement risk. This reform alone is expected to reduce unnecessary litigation by 18–25% in 2026–2027, according to a CNIPA internal impact assessment.

Another critical dimension is the role of the Patent Evaluation Report (专利权评价报告, zhuānlì quán píngjià bàogào). For biologics, these reports are mandatory for patent registration on the linkage platform. In 2026, CNIPA requires that evaluation reports for biologics patents include a stability assessment under actual manufacturing conditions — a specific requirement unique to complex biologic products. Failure to submit a satisfactory evaluation report results in removal of the patent from the platform, effectively removing linkage protection. Between 2023 and 2025, approximately 14% of biologic patents were delisted for evaluation report deficiencies, costing originators an estimated RMB 8–12 million per delisted patent in lost market exclusivity value.

Decision Framework for Biologics Patent Enforcement Strategy

Develop a targeted enforcement strategy based on your product portfolio and patent maturity.

If your biologic product has 3+ registered manufacturing process patents and is within 2 years of expected biosimilar entry, choose the “aggressive litigation” strategy — file patent infringement lawsuits immediately upon biosimilar declaration, leveraging the 9-month stay to invalidate competing manufacturing processes. This approach requires a RMB 3–5 million legal budget per product but yields the highest probability (72% in 2025) of delaying biosimilar entry by 12–18 months.

If your biologic product has 1–2 composition patents with strong validity evidence, and your primary competitor has already received a patent invalidation notice, choose the “settlement-license” strategy — offer a conditional royalty license in exchange for biosimilar market entry delay. This approach reduces litigation costs to approximately RMB 800,000–1.2 million per case and allows you to collect a 5–8% royalty on Chinese biosimilar sales, which averaged RMB 240 million per product in 2025.

If your biologic patents are primarily in the manufacturing realm with uncertain validity, or if your product is beyond 3 years from patent expiry, choose the “defensive registration” strategy — invest in high-quality patent evaluation reports and build a multi-layered patent portfolio with 15+ claims per product. This approach costs approximately RMB 1.5–2.5 million per product in registration and evaluation fees but reduces the risk of platform delisting by 85%.

Three Pitfalls to Avoid in Biologics Patent Linkage